Saniova B, Drobny M, Kneslova L, Minarik M
Department of Anaesthesiology and Intensive Medicine, Comenius University and University Hospital, Martin, Slovak Republic.
J Neural Transm (Vienna). 2004 Apr;111(4):511-4. doi: 10.1007/s00702-004-0112-4. Epub 2004 Feb 17.
To compare our pilot therapeutic results of patients with severe head injury treated either with standard therapy alone or with standard therapy plus amantadine sulphate.
Retrospective pilot study.
Intensive Care Unit (ICU), University Hospital.
All patients with severe head injury (GCS < 8) admitted to the ICU between January 1, 1999 and December 31, 2001. The patients were divided into two groups based on the fact, whether they did or did not receive amantadine sulphate included in standard therapy. Group 1 consisted of 41 patients of average age 42.12 +/- 16.8 years, of them 35 were males and 6 females. Group 2 included 33 patients of average age 43.91 +/- 18.45 years consisting of the 30 males and 3 females.
Both groups were treated with the standard therapy of severe head injury accepted in our institution. In addition, group 1 patients received amantadine sulphate in a dose of 200 mg i.v. twice daily for 3 days, starting on day 3 of hospitalisation. The reason for amantadin sulphate administration was persistent comatos condition.
Glasgow Coma Scale in patients on admission (after resuscitation) and on discharge from the ICU and mortality rate were compared. In the group 1 the average income GCS was 4.47 +/- 2.26 and the average outcome GCS was 9.76 +/- 3.95. In the group 2 the average income GCS was 4.70 +/- 2.14 and the average outcome GCS was 5.73 +/- 3.57. In the amantadine sulphate group two patients out of 33 died (6.06%). There were 17 deaths (51.51%) out of 33 patients in the second control group.
In the group of patients with severe brain injuries treated with standard therapy plus amantadine sulphate the outcome GCS was higher and the case fatality rate lower than in the group treated with standard therapy alone.
比较单纯采用标准疗法与采用标准疗法加硫酸金刚烷胺治疗重型颅脑损伤患者的初步治疗结果。
回顾性初步研究。
大学医院重症监护病房（ICU）。
1999年1月1日至2001年12月31日期间入住ICU的所有重型颅脑损伤（格拉斯哥昏迷量表评分＜8分）患者。根据患者在标准治疗中是否接受硫酸金刚烷胺，将患者分为两组。第1组由41例患者组成，平均年龄42.12±16.8岁，其中男性35例，女性6例。第2组包括33例患者，平均年龄43.91±18.45岁，其中男性30例，女性3例。
两组均采用本机构接受的重型颅脑损伤标准疗法进行治疗。此外，第1组患者从住院第3天开始，接受剂量为200mg静脉注射、每日2次、共3天的硫酸金刚烷胺治疗。给予硫酸金刚烷胺的原因是患者持续昏迷。
比较患者入院时（复苏后）和从ICU出院时的格拉斯哥昏迷量表评分以及死亡率。第1组入院时格拉斯哥昏迷量表评分平均为4.47±2.26分，出院时平均为9.76±3.95分。第2组入院时格拉斯哥昏迷量表评分平均为4.70±2.14分，出院时平均为5.73±3.57分。硫酸金刚烷胺组33例患者中有2例死亡（6.06%）。第二对照组33例患者中有17例死亡（51.51%）。
与单纯采用标准疗法治疗的组相比，采用标准疗法加硫酸金刚烷胺治疗的重型颅脑损伤患者组出院时格拉斯哥昏迷量表评分更高，病死率更低。
